ASH 2019 | Acalabrutinib, venetoclax and obinutuzumab upfront for CLL
Matthew Davids
• 7 Dec 2019
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary safety and efficacy results from an ongoing open-label, single arm, phase II study (NCT03580928) of acalabrutinib, venetoclax and obinutuzumab (AVO) in patients with previously untreated chronic lymphocytic leukemia (CLL). This trial was MRD-guided and Dr Davids highlights the promising efficacy data for AVO. This drug combination will also be studied against chemoimmunotherapy and acalabrutinib plus venetoclax in the phase 3 trial CL-311 (NCT03836261), which is currently enrolling. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
